EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy.

Abstract:

:Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single dose of EPO (60,000 U) in patients with ST-segment elevation myocardial infarction. In a substudy, we aimed to determine the feasibility of cryopreserving and centrally analyzing EPC levels to assess the relationship between EPC numbers, EPO administration, and infarct size. As a prespecified substudy, mononuclear cells were locally cryopreserved before as well as 24 and 48-72 h after primary percutaneous coronary intervention. EPC samples were collected in 163 of 222 enrolled patients. At least one sample was obtained from 125 patients, and all three time points were available in 83 patients. There were no significant differences in the absolute EPC numbers over time or between EPO- and placebo-treated patients; however, there was a trend toward a greater increase in EPC levels from 24 to 48-72 h postintervention in patients receiving ≥30,000 U of EPO (P = 0.099 for CD133(+) cells, 0.049 for CD34(+) cells, 0.099 for ALDH(br) cells). EPC numbers at baseline were inversely related to infarct size (P = 0.03 for CD133(+) cells, 0.006 for CD34(+) cells). Local whole cell cryopreservation and central EPC analysis in the context of a multicenter randomized trial is feasible but challenging. High-dose (≥30,000 U) EPO may mobilize EPCs at 48-72 h, and baseline EPC levels may be inversely associated with infarct size.

journal_name

J Thromb Thrombolysis

authors

Povsic TJ,Najjar SS,Prather K,Zhou J,Adams SD,Zavodni KL,Kelly F,Melton LG,Hasselblad V,Heitner JF,Raman SV,Barsness GW,Patel MR,Kim RJ,Lakatta EG,Harrington RA,Rao SV

doi

10.1007/s11239-013-0944-6

subject

Has Abstract

pub_date

2013-11-01 00:00:00

pages

375-83

issue

4

eissn

0929-5305

issn

1573-742X

journal_volume

36

pub_type

杂志文章,多中心研究,随机对照试验
  • Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.

    abstract::Rivaroxaban is a direct factor Xa inhibitor, which is rapidly absorbed in the upper gastrointestinal (GI) tract. In large trials, it has been shown to be effective and safe in VTE treatment. However, in these trials patients with morbid obesity were not reported and it is unknown if the standard dosage of 20 mg rivaro...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-013-0891-2

    authors: Mahlmann A,Gehrisch S,Beyer-Westendorf J

    更新日期:2013-11-01 00:00:00

  • Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery.

    abstract::Tranexamic acid (TXA) can reduce blood loss and transfusion rates in orthopaedic surgery. In this regard, a new viscoelastometric test (TPA-test, ClotPro), enables the monitoring of TXA effects. This prospective observational study evaluated and correlated TXA plasma concentrations (cTXA) following intravenous and ora...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02272-8

    authors: Groene P,Sappel SR,Saller T,Nitschke T,Sa PA,Paulus A,Chappell D,Schäfer ST

    更新日期:2020-09-12 00:00:00

  • Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.

    abstract::Unfractionated heparin (UFH) plasma protein binding and elimination might be impaired in patients with chronic kidney disease (CKD-defined as creatinine clearance <60 ml/min). It is currently unknown at which UFH bolus dose persistent prolongation of activated partial thromboplastin time (aPTT) occurs in ST-segment el...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-015-1255-x

    authors: Kikkert WJ,van Brussel PM,Damman P,Claessen BE,van Straalen JP,Vis MM,Baan J Jr,Koch KT,Peters RJ,de Winter RJ,Piek JJ,Tijssen JG,Henriques JP

    更新日期:2016-04-01 00:00:00

  • Interhospital transfer on intravenous thrombolysis in patients with acute ischemic stroke in three chinese municipal stroke centers.

    abstract::We included acute ischemic stroke (AIS) patients who received recombinant tissue plasminogen activator (rt-PA) at three stroke centers via either interhospital transfer or direct presentation and compared the clinical outcomes and time metrics to analyze the impact of interhospital transfer on intravenous thrombolysis...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-019-01912-y

    authors: Ding Y,Ji Z,Ma L,Zhai T,Gu Z,Niu J,Liu Y

    更新日期:2019-11-01 00:00:00

  • Molecular pathogenesis of plasminogen Hakodate: the second Japanese family case of severe type I plasminogen deficiency manifested late-onset multi-organic chronic pseudomembranous mucositis.

    abstract::A 64-year-old man first developed ligneous conjunctivitis at the age of 58 years after right pulmonary resection because of suspected cancer; otherwise, he had been healthy. Since then, he began to suffer from various forms of chronic pseudomembranous mucositis. Laboratory tests demonstrated that he had 7.8 % of plasm...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1375-y

    authors: Osaki T,Souri M,Song YS,Izumi N,Law R,Ichinose A

    更新日期:2016-08-01 00:00:00

  • Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report.

    abstract::The outbreak of 2019 novel coronavirus disease (COVID-19) began since early December 2019, and has been declared as a public health emergency by the World Health Organization. Due to the hypercoagulable state, blood stasis and endothelial injury, severe patients with COVID-19 are at high risk for thrombosis. We report...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02084-w

    authors: Zhou B,She J,Wang Y,Ma X

    更新日期:2020-07-01 00:00:00

  • Secondary prevention strategies for coronary heart disease.

    abstract::Patients with established coronary heart disease (CHD) have a high risk of subsequent cardiovascular events, including myocardial infarction (MI), stroke, and death from cardiovascular disease. Adherence to evidence-based secondary prevention therapies for CHD has improved in recent years but still remains suboptimal....

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-009-0381-8

    authors: Weiner SD,Rabbani LE

    更新日期:2010-01-01 00:00:00

  • Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis.

    abstract::This study was intended to evaluate the cost-effectiveness of anticoagulation clinic care and self-testing for the management of patients on chronic warfarin therapy. Using a 5-year Markov model, we evaluated the health and economic outcomes associated with each of three different anticoagulation management approaches...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1018704318655

    authors: Lafata JE,Martin SA,Kaatz S,Ward RE

    更新日期:2000-06-01 00:00:00

  • Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin.

    abstract::Thrombosis resolution is an important component of treatment for deep vein thrombosis (DVT) and multiple anticoagulants are now available. It is unknown whether rivaroxaban contributes to a higher degree of thrombus resolution compared to conventional anticoagulation with warfarin. Our objective was to compare thrombu...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01932-8

    authors: Houghton DE,Lekah A,Macedo TA,Hodge D,Saadiq RA,Little Y,Casanegra AI,McBane RD,Wysokinski WE

    更新日期:2020-02-01 00:00:00

  • Central aortic pulse pressure, thrombogenicity and cardiovascular risk.

    abstract::High central aortic pulse pressure (CPP) and thrombin-induced platelet-fibrin clot strength (TIP-FCS) have been associated with ischemic outcomes in patients with coronary artery disease in separate studies. But, the ischemic risk associated with these factors has never been analyzed in a single study and their interr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-017-1524-y

    authors: Chen G,Bliden KP,Chaudhary R,Liu F,Kaza H,Navarese EP,Tantry US,Gurbel PA

    更新日期:2017-08-01 00:00:00

  • The pharmacology of novel oral anticoagulants.

    abstract::Anticoagulation for the prevention of stroke is an important aspect of the management of atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran have emerged as important therapeutic treatment options for prevention of stroke i...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-013-0967-z

    authors: DeWald TA,Becker RC

    更新日期:2014-01-01 00:00:00

  • Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.

    abstract:UNLABELLED:Platelet P-selectin and activated glycoprotein IIb-IIIa (GPIIb-IIIa) are markers of platelet activation and mediates platelet aggregation. Prasugrel (Pras) 5 mg may be used in very elderly (VE) acute coronary syndrome (ACS) patients undergoing PCI, but its effect on platelet P-selectin and activated GPIIb-II...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-016-1372-1

    authors: Wagner H,Lood C,Borna C,Gidlöf O,Truedsson L,Brown P,Zhou C,Winters K,Jakubowski JA,Erlinge D

    更新日期:2016-10-01 00:00:00

  • Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable

    abstract::Amlodipine, commonly used for relief of ischemic symptoms in coronary artery disease (CAD), may affect clopidogrel-induced antiplatelet effects. It remains unknown if ranolazine, an antianginal drug that constitutes a pharmacologic alternative to calcium channel blockade, interferes with clopidogrel-induced antiplatel...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-015-1203-9

    authors: Pelliccia F,Greco C,Gaudio C,Rosano G,Vitale C,Marazzi G,Rollini F,Angiolillo DJ

    更新日期:2015-10-01 00:00:00

  • Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

    abstract:BACKGROUND:Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-006-7732-5

    authors: Hull RD,Schellong SM,Tapson VF,Monreal M,Samama MM,Turpie AG,Wildgoose P,Yusen RD

    更新日期:2006-08-01 00:00:00

  • Use of oral anticoagulant drugs is associated with carotid intraplaque hemorrhage in atherosclerosis patients: a meta-analysis.

    abstract::Patients with carotid atherosclerosis, especially the elderly population, take antithrombotic medicine regularly. However, no previous meta-analysis has focused on one of the possible side effects of such drugs, namely intraplaque hemorrhage (IPH). To determine whether antiplatelet drugs or anticoagulants are associat...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,meta分析

    doi:10.1007/s11239-019-01865-2

    authors: Cao X,Zhang J,Geng D

    更新日期:2019-07-01 00:00:00

  • Aspirin dosing in cardiovascular disease prevention and management: an update.

    abstract::Aspirin has been in use for prevention and management of cardiovascular diseases for several decades. Clinical and epidemiological literature suggests that while net benefits of aspirin in primary prevention of CVDs are less clear, the benefits of aspirin in acute scenarios and secondary prevention settings are well e...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-015-1267-6

    authors: Ganjehei L,Becker RC

    更新日期:2015-11-01 00:00:00

  • SARS-CoV-2 infection and thrombotic complications: a narrative review.

    abstract::The current, global situation regarding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and its potentially devastating clinical manifestations, i.e. coronavirus disease 2019 (COVID-19), took the world by storm, as millions of people have been infected worldwide and more than 1,600,000 patien...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-020-02374-3

    authors: Moschonas IC,Tselepis AD

    更新日期:2021-01-15 00:00:00

  • Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study.

    abstract::D-dimer levels are increased in patients with acute pulmonary embolism (PE). However, D-dimer levels are also increased in patients with community-acquired pneumonia (CAP). The aim of this prospective cohort study was to examine the incidence and clinical features of patients preliminarily diagnosed with CAP and with ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-015-1275-6

    authors: Zhang Y,Zhou Q,Zou Y,Song X,Xie S,Tan M,Zhang G,Wang C

    更新日期:2016-05-01 00:00:00

  • Risk factors for intracerebral hemorrhage in patients with COVID-19.

    abstract::Intracerebral hemorrhage (ICH) can be a devastating complication of coronavirus disease (COVID-19). We aimed to assess risk factors associated with ICH in this population. We performed a retrospective cohort study of adult patients admitted to NYU Langone Health system between March 1 and April 27 2020 with a positive...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02288-0

    authors: Melmed KR,Cao M,Dogra S,Zhang R,Yaghi S,Lewis A,Jain R,Bilaloglu S,Chen J,Czeisler BM,Raz E,Lord A,Berger JS,Frontera JA

    更新日期:2020-09-24 00:00:00

  • Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

    abstract::Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists. No specific reversal agent for factor Xa (FXa) direct inhibitors is currently available for clinical use. A modified activated human FXa decoy protein, andexan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1617-2

    authors: Sartori M,Cosmi B

    更新日期:2018-04-01 00:00:00

  • Implications of an inpatient warfarin dosing nomogram on safety outcomes post-discharge.

    abstract::Many hospitals have implemented warfarin dosing nomograms to improve patient safety. To our knowledge, no study has assessed the impact inpatient warfarin initiation has in both medical and surgical patients, on safety outcomes post discharge. To evaluate the impact of a suggested institutional nomogram for the initia...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1462-0

    authors: Chamoun N,Macías CG,Donovan JL,Klugman R,Gore J,Salameh P,Tran MT

    更新日期:2017-05-01 00:00:00

  • Inhibition of collagen, and thrombin-induced platelet aggregation by Lansberg's hognose pit viper (Porthidium lansbergii hutmanni) venom.

    abstract::The Porthidium genus is represented by the P. lansbergii rozei and P. lansbergii hutmanni (Plh) subspecies in Venezuela. The venom components of these have been little studied, probably due to the low incidence of reported accidents, although acute and serious local effects such as invasive edema and disseminated ecch...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0040-x

    authors: López-Johnston JC,de Bosch N,Scannone H,Rodríguez-Acosta A

    更新日期:2007-12-01 00:00:00

  • Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds.

    abstract::The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring, however emergency measurements are gaining importance. Current assays feature good performance at intermediate and high dabigatran concentrations but show limited accuracy at low concentrations. This area requires more attention as ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-019-01981-z

    authors: Härtig F,Poli S,Ebner M,Birschmann I,Kuhn J,Ziemann U,Häring HU,Lehmann R,Peter A,Hörber S

    更新日期:2020-04-01 00:00:00

  • A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic.

    abstract::Management of intermediate and high risk acute pulmonary embolism (PE) is challenging. The role of multidisciplinary teams for the care of these patients is emerging. Herein, we report our experience with a pulmonary embolism response team (PERT). We conducted a retrospective chart review on all patients admitted to t...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1686-2

    authors: Mahar JH,Haddadin I,Sadana D,Gadre A,Evans N,Hornacek D,Mahlay NF,Gomes M,Joseph D,Serhal M,Tong MZ,Bauer SR,Militello M,Silver B,Shishehbor M,Bartholomew JR,Heresi GA

    更新日期:2018-08-01 00:00:00

  • Coronary artery fistulae.

    abstract::Coronary artery fistulae (CAF) are rare congenital or acquired in which a connection forms between one of the coronary arteries and a heart chamber or with other vessels. This paper describes three cases of CAF along with their initial presentation, imaging findings and management. The first case is a rare form of CAF...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-019-01897-8

    authors: Ali M,Kassem KM,Osei K,Effat M

    更新日期:2019-08-01 00:00:00

  • Mitochondria and chronic effects of cancer therapeutics: The clinical implications.

    abstract::One of the major mechanisms of action of chemo-radiation is to induce cellular senescence, which exerts crucial roles in age-related pathology. The concept of senescence is evolved, and the novel understanding of senescence-associated reprogramming/stemness has emerged. This new concept emphasizes senescence as not on...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-020-02313-2

    authors: Dominic A,Hamilton D,Abe JI

    更新日期:2020-10-20 00:00:00

  • Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes.

    abstract::Venous thromboembolism (VTE) is a common complication of hematologic malignancies. Prolonged periods of thrombocytopenia are experienced universally by patients undergoing treatment for these diseases, yet data to guide management of anticoagulation in this setting are lacking. To obtain data on the management and out...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-017-1539-4

    authors: Samuelson Bannow BT,Walter RB,Gernsheimer TB,Garcia DA

    更新日期:2017-11-01 00:00:00

  • Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.

    abstract::Limited evidence exists regarding management of recurrent venous thromboembolism (VTE) that occurs during anticoagulant therapy. We aimed to describe patient characteristics, drug therapy management, and outcomes of patients with VTE recurrence during anticoagulant therapy. We identified 30 relevant episodes of VTE re...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-021-02377-8

    authors: Lai N,Jones AE,Johnson SA,Witt DM

    更新日期:2021-01-23 00:00:00

  • Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.

    abstract::Ischemic stroke and major bleeding, mostly due to intracranial hemorrhage (ICH), cause about the same rates of death in pivotal randomized trials of direct oral anticoagulants (DOACs) versus warfarin for stroke prevention in atrial fibrillation (AF). We analyzed our AF inpatient database to determine whether any ICH-r...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1767-2

    authors: Chopard R,Piazza G,Hurwitz S,Fanikos J,Goldhaber SZ

    更新日期:2019-02-01 00:00:00

  • Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.

    abstract::To analyze the efficacy and safety of activated prothrombin complex concentrates (aPCC) and four-factor prothrombin complex concentrates (4F-PCC) to prevent hematoma expansion in patients taking apixaban or rivaroxaban with intracranial hemorrhage (ICH). In this multicenter, retrospective study, sixty-seven ICH patien...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02154-z

    authors: Castillo R,Chan A,Atallah S,Derry K,Baje M,Zimmermann LL,Martin R,Groysman L,Stern-Nezer S,Minokadeh A,Nova A,Huang W,Cang W,Schomer K

    更新日期:2021-01-01 00:00:00